Skip to main content
. Author manuscript; available in PMC: 2024 Jan 3.
Published in final edited form as: J Am Coll Cardiol. 2022 Oct 31;81(1):16–30. doi: 10.1016/j.jacc.2022.10.008

Figure 5. Pre-specified subgroup analysis.

Figure 5.

Pooled results indicate that patients assigned to DOACs compared with patients assigned to VKAs had higher odds of developing arterial thrombotic events without clear effect modification based on the type of APS (triple-positive vs any other combination), sex, or history of arterial thrombosis (vs no prior arterial thrombosis). The rates of VTE and major bleeding were not significantly different between the two treatment arms, regardless of the subgroup category.